All Eyes Are On SCRC
Yes Kenbe, Views could hit well over 2000 TODAY!
ScripsAmerica Daily: The
company’s recent expansion plans
through sourcing agreements,
including its newly acquired
licensing to distribute and market
pharmaceutical products in 12 new
states, will aim to raise both the
presence and stock price for the
company.
The current stock price hovers
around the low-mid range of the
52 weeks range ($0.08 - $0.26)
with rising prices observed over
the past month. The MACD
indicator exhibits a buy signal
since October 2014 and the
trend is likely to continue in the
foreseeable future, especially
combined with the company’s
rising revenue and expansion
plans.
On the other side, there could
be a weakening indicator for
buy signal as the market
adjusts. Investors need to watch
out for potential market reversal,
which could be expected in the
very near future.
Volume has been high for the
past month, however there are
signs of less trading activity,
which is consistent with the
potential reversal activity.
The current stock price of
$0.125 is a critical resistance
level, which has been tested in
September. If the market breaks
the resistance, there’s a
reasonably high likelihood that
the price will make a significant
breakthrough persistently,
otherwise a reversal is
expected.
ScripsAmerica Inc. (SCRC $0.13)
Footnotes and disclaimers are contained in the last page of this report. Page 2
ScripsAmerica’s main competitive advantages lie in its strong customer retention, low cost and
access to wide customer base. The firm is able to cater to a large base of customers without
carrying a substantial amount of inventory. This demonstrates ScripsAmerica’s ability of flawless
execution of management in a pure generic market. One of the significant players in the field is
McKesson Corporation. McKesson Corporation is an American company distributing
pharmaceuticals at a retail sale level and providing health information technology, medical
supplies, and care management tools. With the Market Capitalization of $42.7B, McKesson is not
a direct competitor with ScripsAmerica, but it is one of the largest players in the industry. In
January 2014, McKesson announced an acquisition with Celesio, an international pharmacy
retailer and provider of logistics and services to the pharmaceutical and healthcare sector. This
makes McKesson possesses even more power over the industry, and suggests ScripsAmerica
focusing on sharpen its competitive advantages and continuously revise its strategies to maintain
market shares and seek growth.
The company is considering to undertake several strategic ventures, including collaborating with
Forbes Investment Ltd. and dive deeper into the Chinese OTC market. Arrangements are being
made to create an upcoming slaes agreement that would introduce RapiMed ® into the Chinese
OTC drug market.
“Since Scrips began managing Main Avenue Pharmacy six months ago, its sales revenue
generated by filling the Company’s prescriptions has steadily increased each month, reaching
nearly $5.5 million in September. We expect the revenue from ScripsAmerica’s specialty
pharmacy operations to remain strong during the fourth quarter and potentially increase in 2015
as we continue to expand our presence in this market across the country,” commented
ScripsAmerica’s CEO Bob Schneiderman.
Conclusion: SCRC’s stock has recently hit an all-time low of $0.0815. However, the company
reported significant growth in revenues that put the SCRC ahead of many of its competitors with
similar financial standing. The most accepted market valuation is $16 million, and these investors
bet on that the $0.0815 was the all-time low and the market reversal point. As of current, the
$0.125 price point could also be a reversal point for the rising price and increasing volume. In
summary, SCRC is a potentially profitable stock in the short run over the next few weeks and
months. The stock is recommended for speculators looking for an overall long position on trades
with occasional short trades.
DIS
Yes Kenbe, Views could hit well over 2000 TODAY!
ScripsAmerica Daily: The
company’s recent expansion plans
through sourcing agreements,
including its newly acquired
licensing to distribute and market
pharmaceutical products in 12 new
states, will aim to raise both the
presence and stock price for the
company.
The current stock price hovers
around the low-mid range of the
52 weeks range ($0.08 - $0.26)
with rising prices observed over
the past month. The MACD
indicator exhibits a buy signal
since October 2014 and the
trend is likely to continue in the
foreseeable future, especially
combined with the company’s
rising revenue and expansion
plans.
On the other side, there could
be a weakening indicator for
buy signal as the market
adjusts. Investors need to watch
out for potential market reversal,
which could be expected in the
very near future.
Volume has been high for the
past month, however there are
signs of less trading activity,
which is consistent with the
potential reversal activity.
The current stock price of
$0.125 is a critical resistance
level, which has been tested in
September. If the market breaks
the resistance, there’s a
reasonably high likelihood that
the price will make a significant
breakthrough persistently,
otherwise a reversal is
expected.
ScripsAmerica Inc. (SCRC $0.13)
Footnotes and disclaimers are contained in the last page of this report. Page 2
ScripsAmerica’s main competitive advantages lie in its strong customer retention, low cost and
access to wide customer base. The firm is able to cater to a large base of customers without
carrying a substantial amount of inventory. This demonstrates ScripsAmerica’s ability of flawless
execution of management in a pure generic market. One of the significant players in the field is
McKesson Corporation. McKesson Corporation is an American company distributing
pharmaceuticals at a retail sale level and providing health information technology, medical
supplies, and care management tools. With the Market Capitalization of $42.7B, McKesson is not
a direct competitor with ScripsAmerica, but it is one of the largest players in the industry. In
January 2014, McKesson announced an acquisition with Celesio, an international pharmacy
retailer and provider of logistics and services to the pharmaceutical and healthcare sector. This
makes McKesson possesses even more power over the industry, and suggests ScripsAmerica
focusing on sharpen its competitive advantages and continuously revise its strategies to maintain
market shares and seek growth.
The company is considering to undertake several strategic ventures, including collaborating with
Forbes Investment Ltd. and dive deeper into the Chinese OTC market. Arrangements are being
made to create an upcoming slaes agreement that would introduce RapiMed ® into the Chinese
OTC drug market.
“Since Scrips began managing Main Avenue Pharmacy six months ago, its sales revenue
generated by filling the Company’s prescriptions has steadily increased each month, reaching
nearly $5.5 million in September. We expect the revenue from ScripsAmerica’s specialty
pharmacy operations to remain strong during the fourth quarter and potentially increase in 2015
as we continue to expand our presence in this market across the country,” commented
ScripsAmerica’s CEO Bob Schneiderman.
Conclusion: SCRC’s stock has recently hit an all-time low of $0.0815. However, the company
reported significant growth in revenues that put the SCRC ahead of many of its competitors with
similar financial standing. The most accepted market valuation is $16 million, and these investors
bet on that the $0.0815 was the all-time low and the market reversal point. As of current, the
$0.125 price point could also be a reversal point for the rising price and increasing volume. In
summary, SCRC is a potentially profitable stock in the short run over the next few weeks and
months. The stock is recommended for speculators looking for an overall long position on trades
with occasional short trades.
DIS
